Virtu Financial LLC Increases Holdings in Cencora, Inc. (NYSE:COR)

Virtu Financial LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 112.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,227 shares of the company's stock after buying an additional 5,407 shares during the quarter. Virtu Financial LLC's holdings in Cencora were worth $2,302,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of COR. Pacer Advisors Inc. increased its holdings in shares of Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after acquiring an additional 2,035,679 shares in the last quarter. Bank of Montreal Can raised its holdings in Cencora by 136.8% during the second quarter. Bank of Montreal Can now owns 641,887 shares of the company's stock worth $153,623,000 after buying an additional 370,841 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Cencora by 155.0% in the second quarter. American Century Companies Inc. now owns 598,438 shares of the company's stock valued at $134,828,000 after buying an additional 363,796 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Cencora by 7.0% during the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after buying an additional 338,452 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Cencora by 21.7% during the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock worth $368,771,000 after acquiring an additional 292,600 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Stock Performance

NYSE COR traded up $0.12 during trading hours on Friday, reaching $232.24. 773,147 shares of the company were exchanged, compared to its average volume of 1,386,901. The stock has a market capitalization of $44.89 billion, a P/E ratio of 30.92, a P/E/G ratio of 1.54 and a beta of 0.45. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 1 year low of $195.83 and a 1 year high of $253.27. The business's 50 day simple moving average is $238.36 and its 200-day simple moving average is $233.91.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date was Friday, November 15th. Cencora's dividend payout ratio (DPR) is currently 29.29%.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Barclays boosted their price objective on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Mizuho assumed coverage on Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. Evercore ISI upped their target price on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Finally, Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and an average target price of $275.60.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company's stock, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 93,018 shares of company stock worth $22,478,942 over the last ninety days. 15.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.